Fig 1: Immunohistochemical analysis(A) Low density PD-L1+ stromal cells, (B) High density PD-L1+ stromal cells, (C) Low intensity PD-L1+ tumor epithelial cells, (D) High intensity PD-L1+ tumor epithelial cells, (E) Negative isotype control antibody for PD-L1 (prostate TMA), (F) Negative control for PD-L1 (brain), (G) Positive control for PD-L1 (placenta), (H) Low density of intratumoral PD-1+ lymphocytes, (I) High density of intratumoral PD-1+ lymphocytes, (J) PD-1 and CD8 double stain with pink showing PD-1 positivity, and brown showing CD8 positivity, (K) Negative isotype control antibody for PD-1, (L) Negative control for PD-1 (brain), (M) Positive control for PD-1 (tonsil), (N) Positive control for PD-1 and CD8 double stain (tonsil). Magnification ×400 for all, except (N) which shows ×50 magnification.
Fig 2: Biochemical failure-free survival curves for PD-L1 intensity in tumor epithelial cellsGrey lines indicate low intensity, whereas black lines indicate high intensity.
Supplier Page from OriGene Technologies for PD-L1 (CD274) (NM_014143) Human Over-expression Lysate